Healthcare Data Analytics companies received $826 million in venture capital in the first half (1H) of 2020, according to Mercom Digital Health Funding and M&A Report. Twenty-seven percent of the $826 million went into AI-powered healthcare data analytics companies.
Over 100 investors participated in data analytics financing activity during 1H 2020. GV (formerly Google Ventures), Andreessen Horowitz, Bpi France, and Healthworx led the financing activity with multiple rounds. The top five funding deals accounted for almost 60% of the total funding in 1H 2020.
Top funded analytics companies 1H 2020:
DNAnexus, a cloud-based genomic and clinical data management software platform, closed a $100M in Series G funding round. Perceptive Advisors and Northpond Ventures co-led the financing round, with Foresite Capital, TPG Capital, First Round Capital, Regeneron Pharmaceuticals, and GV (formerly Google Ventures), the venture capital investment arm of Alphabet.
California-based real-world clinical data analytics company Verana Health (formerly DigiSight) announced the closing of a $100 million investment round. GV (formerly Google Ventures) led the financing round with participation from new investors.
Genetic analysis application developer Element Biosciences raised $80.3 million in Series B funding. New investors Fidelity Management & Research Company and JS Capital participated in the round, along with existing investors Foresite Capital and Venrock.
Innovaccer, a unified healthcare data activation platform, raised $70 million in Series C funding from Steadview Capital, Tiger Global, Dragoneer, Westbridge, Mubadala, and M12 (Microsoft’s Venture Fund). Innovaccer has raised a total of $120M to date, including $35M in Series B funding, and $15.6M in Series A funding in 2016.
Omniome, the developer of a DNA-sequencing platform, raised an additional $60M with the completion of its Series C financing. The funding round was led by Madrone Capital Partners. Current investors include ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Sciences Ventures, and Nan Fung Life Sciences.
nference, a provider of AI-powered software platform to synthesize biomedical knowledge enhancing drug discovery, clinical research, and operations, raised $60M in Series B funding. Mayo Clinic participated in the round as a strategic investor. NTT Venture Capital participated with existing investors – Matrix Partners and Matrix Capital Management also joining in.
